London South East

European Patent Granted for MED3000 until 2040

European Patent Office grants patent for MED3000 providing protection to 2040 Futura Medical plc (AIM: FUM), the pharmaceutical company developing innovative sexual health products, today announces ...
PharmiWeb

Futura Announces Collaboration with Cooper Consumer Health to Commercialise MED3000 in EEA, United Kingdom and Switzerland

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on ...
London South East

Pre-launch of MED3000 ahead of H1 2023 launch | Regulatory News

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on ...
PharmiWeb

US FDA Grants for Over-the-Counter Marketing Authorization to Futura for Fast-Acting Topical Gel, MED3000, to Treat Erectile Dysfunction

- Company also announced that it raised proceeds of £4,375,000 to fund future commercialization of MED3000 via a warrant exercise by a large institutional shareholder - GUILDFORD, England--(BUSINESS ...
pharmaphorum

Futura seeks EU approval of erectile dysfunction gel as medical device

UK biotech Futura Medical has said it will seek approval for its MED3000 topical treatment for erectile dysfunction in Europe, using a medical devices pathway. Futura says MED3000 has a unique ...